Udzire
Udzire Uses, Dosage, Side Effects, Food Interaction and all others data.
Udzire is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena. It is not yet approved for use in the U.S., E.U., or Canada.
Udzire is a potent selective phosphodiesterase type 5 (PDE5) inhibitor.
| Trade Name | Udzire |
| Generic | Udenafil |
| Udenafil Other Names | Udenafil |
| Weight | 100mg |
| Type | Tablet |
| Formula | C25H36N6O4S |
| Weight | Average: 516.656 Monoisotopic: 516.25187436 |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | Zydus Cadila Healthcare Ltd |
| Available Country | India |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Udzire is a PDE5 inhibitor used to treat erectile dysfunction.
Investigated for use/treatment in erectile dysfunction and hypertension.
Udzire is also used to associated treatment for these conditions: Erectile Dysfunction
How Udzire works
Udzire inhibits the cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) by udenafil enhances erectile function by increasing the amount of cGMP.
Innovators Monograph
You find simplified version here Udzire
